[{"orgOrder":0,"company":"IAVI","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IAVI \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"IAVI \/ Merck Group"},{"orgOrder":0,"company":"IAVI","sponsor":"Biofabri","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"IAVI \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ IAVI"},{"orgOrder":0,"company":"IAVI","sponsor":"Zendal","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"IAVI \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ IAVI"},{"orgOrder":0,"company":"IAVI","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Intradermal Injection","sponsorNew":"IAVI \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"IAVI","sponsor":"German Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intradermal Injection","sponsorNew":"IAVI \/ German Government","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ German Government"},{"orgOrder":0,"company":"IAVI","sponsor":"Biofabri","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"IAVI \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ IAVI"},{"orgOrder":0,"company":"IAVI","sponsor":"IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ IAVI","highestDevelopmentStatusID":"8","companyTruncated":"IAVI \/ IAVI"},{"orgOrder":0,"company":"IAVI","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"rVSV\u2206G-LASV-GPC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Merck & Co"},{"orgOrder":0,"company":"IAVI","sponsor":"Scripps Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS01B","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ IAVI","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ IAVI"},{"orgOrder":0,"company":"IAVI","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"eOD-GT8 60mer","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ IAVI","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ IAVI"},{"orgOrder":0,"company":"IAVI","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1644","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Moderna Therapeutics"},{"orgOrder":0,"company":"IAVI","sponsor":"Moderna Therapeutics | George Washington University | Fred Hutchinson Cancer Center | Gabrail Cancer Center Research | UT Health San Antonio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"eOD-GT8 60mer mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"IAVI \/ Moderna Therapeutics | George Washington University | Fred Hutchinson Cancer Center | Gabrail Cancer Center Research | UT Health San Antonio","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Moderna Therapeutics | George Washington University | Fred Hutchinson Cancer Center | Gabrail Cancer Center Research | UT Health San Antonio"},{"orgOrder":0,"company":"IAVI","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"rVSV\u2206G-SEBOV-GP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ BARDA"},{"orgOrder":0,"company":"IAVI","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"eOD-GT8 60mer mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Moderna Therapeutics"},{"orgOrder":0,"company":"IAVI","sponsor":"Polymun Scientific Immunbiologische Forschung GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MOS1SIP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ Polymun Scientific Immunbiologische Forschung GmbH","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Polymun Scientific Immunbiologische Forschung GmbH"},{"orgOrder":0,"company":"IAVI","sponsor":"GSK | Rockefeller University | George Washington University | Amsterdam UMC, VUmc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ GSK | Rockefeller University | George Washington University | Amsterdam UMC, VUmc","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ GSK | Rockefeller University | George Washington University | Amsterdam UMC, VUmc"},{"orgOrder":0,"company":"IAVI","sponsor":"AURUM Tembisa Clinical Research | Center for Family Health Research | Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"eOD-GT8 60mer mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ AURUM Tembisa Clinical Research | Center for Family Health Research | Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ AURUM Tembisa Clinical Research | Center for Family Health Research | Moderna Therapeutics"},{"orgOrder":0,"company":"IAVI","sponsor":"3M Company | Access to Advanced Health Institute | Polymun Scientific Immunbiologische Forschung GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BG505 SOSIP.664 gp140 Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ 3M Company | Access to Advanced Health Institute | Polymun Scientific Immunbiologische Forschung GmbH","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ 3M Company | Access to Advanced Health Institute | Polymun Scientific Immunbiologische Forschung GmbH"},{"orgOrder":0,"company":"IAVI","sponsor":"Ragon Institute | ReiThera | Mutala Trust","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GRAdHIVNE1 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ Ragon Institute | ReiThera | Mutala Trust","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Ragon Institute | ReiThera | Mutala Trust"},{"orgOrder":0,"company":"IAVI","sponsor":"Batavia Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VSV\u2206G-SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ IAVI"},{"orgOrder":0,"company":"IAVI","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVSV\u0394G-SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ BARDA"},{"orgOrder":0,"company":"IAVI","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"rVSV\u2206G-LASV-GPC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ CEPI"},{"orgOrder":0,"company":"IAVI","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"rVSV\u0394G-MARV-GP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ BARDA"},{"orgOrder":0,"company":"IAVI","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVSV Based Covid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ IAVI"}]
Find Clinical Drug Pipeline Developments & Deals by IAVI
Details :
MTBVAC is a live-attenuated vaccine candidate, derived from a human isolate of Mycobacterium tuberculosis. It is being evaluated to prevent active TB lung disease in adolescents and adults.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) :
Mycobacterium Tuberculosis Vaccine, Live Attenuated
Details :
A vaccine candidate, is being investigated in a phase 2 trial in above 2 years older Nigerian population for the prevention of Lassa fever virus infection.
Details :
The net proceeds will be used to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) :
Mycobacterium Tuberculosis Vaccine, Live Attenuated
Details :
The funding will support the late-stage development of MTBVAC, a live, attenuated Mycobacterium tuberculosis vaccine, currently being developed as a potentially longer-lasting TB vaccine for newborns and for the prevention of TB disease in adults and ado...
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
July 07, 2023
Lead Product(s) :
Mycobacterium Tuberculosis Vaccine, Live Attenuated
Details :
Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) :
Mycobacterium Tuberculosis Vaccine, Live Attenuated
Details :
The funding will be used in the development and testing of IAVI's single-dose vaccine candidates, rVSVΔG-MARV-GP and rVSVΔG-SUDV-GP, against the filoviruses Marburg virus (MARV) and Sudan ebolavirus (SUDV) respectively.
Reset All
